epinephrine · Bpi Labs · NDA 205029, 209359, 211363, 215425, 220626

Epinephrine

Earliest generic entry, as listed · earliest of 8 marketed strengths
17 Jan 2045

7 of 8 marketed strengths have no unexpired patent or exclusivity listed.

Blocked by patent: US 12539283.

Listed patents · 1 unexpired

PatentClaimsExpires
US 12539283drug product · sets the listed date17 Jan 2045

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 10

NDA · productFormStrengthListed expiry
205029 · 001 · RLDsolution, intravenous, intraocular, intramuscular, subcutaneous1MG/ML (1MG/ML)open
205029 · 002 · RLDsolution, intramuscular, intravenous, subcutaneous10MG/10ML (1MG/ML)open
205029 · 003 · RLD · discontinuedsolution, intravenous1MG/ML (1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**open
205029 · 004 · RLDsolution, intramuscular, intravenous, subcutaneous30MG/30ML (1MG/ML)open
205029 · 005 · RLDsolution, intramuscular, intravenous, subcutaneous1MG/ML (1MG/ML)open
209359 · 001 · RLD · discontinuedsolution, intravenous1MG/10ML (0.1MG/ML)open
211363 · 001 · RLDsolution, intravenous1MG/10ML (0.1MG/ML)open
215425 · 001 · RLDsolution, intramuscular, intravenous, subcutaneous30MG/30ML (1MG/ML)17 Jan 2045
220626 · 001 · RLDsolution, intramuscular, intravenous, subcutaneous1MG/ML (1MG/ML)open
220626 · 002 · RLDsolution, intramuscular, intravenous, subcutaneous30MG/30ML (1MG/ML)open